Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.
Information source: Britannia Pharmaceuticals Ltd.
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Parkinson's Disease
Intervention: Apomorphine Nasal Powder (Drug)
Phase: Phase 2/Phase 3
Status: Not yet recruiting
Sponsored by: Britannia Pharmaceuticals Ltd. Official(s) and/or principal investigator(s):
Richard Weiser, MB, MRCP, Principal Investigator, Affiliation: Swansea Hospital, Swansea, Wales
Summary
To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in
subjects with Parkinson's Disease.
Clinical Details
Study design: Randomized, Double-Blind, Placebo Control, Parallel Assignment
Eligibility
Minimum age: 18 Years.
Maximum age: 85 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 1 year history of Parkinson's Disease; stable PD medications for 4 weeks; at least
one documented "off" period per day
Exclusion Criteria:
- hypersensitivity to apomorphine; participation in a clinical trial in the last 12
weeks; pregnant or lactating females
Locations and Contacts
Additional Information
Last updated: June 29, 2006
|
